FDA Approves Nerlynx-Capecitabine Combo for HER2-positive Metastatic Breast Cancer
News
Nerlynx (neratinib) is now approved in the U.S. for use, in combination with capecitabine, to treat HER2-positive breast cancer patients who have received two or more HER2-targeted therapies for their metastatic ... Read more